Tiziana Life Sciences Prices $10M Direct Offering
Ticker: TLSA · Form: 6-K · Filed: Nov 1, 2024 · CIK: 1723069
Sentiment: neutral
Topics: offering, capital-raise, common-stock
TL;DR
Tiziana Life Sciences just sold 5.2M shares for $10M to an institutional investor. Cash infusion incoming.
AI Summary
On October 30, 2024, Tiziana Life Sciences Ltd. entered into a securities purchase agreement with an institutional investor to sell 5,263,158 common shares. The offering is expected to raise approximately $10 million before deducting offering expenses.
Why It Matters
This capital raise provides Tiziana Life Sciences with funds that can be used for ongoing operations and potential development of its pharmaceutical products.
Risk Assessment
Risk Level: medium — The company is raising capital through a direct offering, which can dilute existing shareholders and may indicate a need for funds.
Key Numbers
- 5,263,158 — Common Shares Sold (Number of shares purchased by an institutional investor.)
- $10 million — Gross Proceeds (Estimated amount raised before expenses from the sale of common shares.)
Key Players & Entities
- Tiziana Life Sciences Ltd. (company) — Registrant
- October 30, 2024 (date) — Date of Purchase Agreement
- 5,263,158 (dollar_amount) — Number of common shares sold
- $10 million (dollar_amount) — Gross proceeds from the offering
FAQ
What is the price per share in the registered direct offering?
The filing states the aggregate amount of the offering is approximately $10 million for 5,263,158 shares, implying a price of approximately $1.90 per share, though the exact price per share is not explicitly stated.
Who is the institutional investor purchasing the shares?
The filing refers to the purchaser only as 'an institutional investor' and does not disclose its specific name.
What will the net proceeds from the offering be used for?
The filing does not specify the exact use of the net proceeds, but it is implied they will be used for general corporate purposes and operations.
When is the closing of the offering expected?
The filing does not provide an expected closing date for the offering.
Are there any conditions to closing the purchase agreement?
The filing mentions a 'securities purchase agreement' but does not detail specific closing conditions.
Filing Stats: 1,060 words · 4 min read · ~4 pages · Grade level 13.9 · Accepted 2024-10-31 20:38:57
Key Financial Figures
- $0.001 — ompany’s common shares, par value $0.001 per share, at a purchase price of $0.95
- $0.95 — 0.001 per share, at a purchase price of $0.95 per share in a registered direct offeri
- $5 million — irect Offering will total approximately $5 million. The Company also granted such investor
Filing Documents
- ea0219524-6k_tiziana.htm (6-K) — 29KB
- ea021952401ex5-1_tiziana.htm (EX-5.1) — 12KB
- ea021952401ex10-1_tiziana.htm (EX-10.1) — 178KB
- ea021952401ex10-2_tiziana.htm (EX-10.2) — 194KB
- ea021952401ex99-1_tiziana.htm (EX-99.1) — 10KB
- ex5-1_001.jpg (GRAPHIC) — 4KB
- ex5-1_002.jpg (GRAPHIC) — 6KB
- 0001213900-24-093101.txt ( ) — 438KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LIMITED Date: November 1, 2024 By: /s/ Ivor Elrifi Name: Ivor Elrifi Title: Chief Executive Officer 3